Macrophages in Athersclerosis Flashcards

1
Q

What is the primary role of macrophages, and how do they do this?

A

The identification and degradation of pathogens, cell debris and cancer cells – endocytosing them via pattern recognition receptors and engulfing them in a phagosome, which then merges with the lysosome to degrade the pathogen before exocytosing the remnant material and displaying the antigens.

The activity of this process triggers the release of pro-inflammatory cytokines.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How are macrophages attracted to the endothelium?

A

Monocytes are attracted to the endothelium by chemokine attractants such as CCL5 and CXCL1, which are released due to the inflammation caused by LDL accumulation and subsequent endothelial activation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How are macrophages recruited into the endothelium?

A

The monocytes are recruited via diapedesis by the monocyte P-selectin glycoprotein ligand 1 (PGSL-1) when rolling and their firm adhesion is facilitated by binding the VLA-4 and LFA-1 integrins which dimerise with VCAM and ICAM respectively to mediate internalisation (E-selectin also being involved in these processes).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How does platelet recruitment to the endothelium in atherosclerosis affect macrophage recruitment?

A

It promotes monocyte-endothelium interactions through deposition of platelet-derived chemokines and its activation of NF-κB signalling, leading to increased expression of VCAM and ICAM.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How does CVD affect the immune cells?

A

Monocytes can in fact be modified prior to their recruitment by the high levels of plasma cholesterol characteristic of CVD.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How does high cholesterol affect monocytes?

A

During the production of monocytes from their bone-marrow derived progenitors (HSPCs – haematopoeitic stem/progenitor cells) the cholesterol begins to induce their later phenotype and also increase the numbers of monocytes in circulation.

This is mediated by cholesterol increasing the IL-3 concentration and stimulating the GM-CSF (granulocyte macrophage – CSF) receptor, both of which stimulate proliferation of the monocytes. In ApoE -/- mice monocyte levels are 50% higher than in wildtype.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What happens when monocytes are first internalised into the endothelium?

A

Once internalised these differentiate into macrophages due to monocyte colony stimulating factor (M-CSF) signalling and proliferate within the plaque.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the intended function of the macrophage within the fatty streak?

A

In the early stages these macrophages serve their intended purpose – clearing the apoptotic cells and LDLs from the lesion or fatty streak.

The LDLs taken up at this stage, even those taken up by scavenger receptors such as SR-A or CD36, are hydrolysed in endosomes and the cholesterol trafficked to the ER via the NPC1/2 pathway.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What effect does the OD of LDL have on the macrophages in the lesion?

A

Much of this free cholesterol is effluxed via ABCG1, but the large excess leads to esterification by ACAT and storage within the cell to produce foam cells.

Upregulating cholesterol efflux in macrophages is thus a major therapeutic target, as this is the primary mechanism of plaque regression.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What dysregulation occurs in foam cells due to the high lipid content?

A

The oxysterols and modified PLs from atherogenic lipoprotein uptake (ApoB-LPs) can lead to macrophage apoptosis, or in lesser conditions can enrich the plasma membrane with free cholesterol which activates inflammatory signalling receptors leading to increased cytokine production.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How do foam cells progress the lesion?

A

This is sufficiently worsened by their uncontrollable oxLDLs uptake (cholesterol loading) to produce enough foam cells to form a lipid lesion core.

New macrophages are still active at this point, but then promote progression of the lesion through degradation of the fibrous cap and thrombotic core formation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are cholesterol crystals?

A

A hallmark of advanced atherosclerosis that forms within lipid cores and is highly pro-inflammatory.

Macrophages attempt to engulf the cholesterol crystals, but this just makes everything worse.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How do cholesterol crystals affect macrophages?

A

During engulfing they cause endosome damage and subsequent lysosomal disruption, which in conjunction with the subsequent impairment of cathepsin B and L and hence the sterol response network, prevents proper cholesterol management and is hence highly pro-atherogenic.

Also by activating the macrophage inflammasome complex composed of NLRP3, ASC and caspase-1. This leads to increased IL-1β and IL-18 secretion, which act as chemokines to attract more monocytes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What factors promote foam cell apoptosis in the lesion core?

A

Prolonged ER stress in the overloaded foam cells, as well as the often hypoxic conditions, lack of growth factors and activation of death receptors (IFN and TLR3/4 signalling), triggers apoptosis of the foam cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What factors prevent foam cell apoptosis in the lesion core?

A

In some cells this is prevented by the ER stress activating cell survival pathways including NF-κB, Akt, p38 kinases and autophagy, thus reducing necrotic core formation. This is, however, inhibited by the uptake of LDLs via scavenger receptors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How does macrophage/foam cell apoptosis impact formation of the necrotic core and lesion progression?

A

Macrophage apoptosis itself does not cause necrosis, but defective clearance of the products by the remaining macrophages leads to secondary necrosis and formation of the necrotic core.

Macrophage cell death in early lesions can actually be beneficial, decreasing the inflammation and number of foam cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How do macrophages promote plaque rupture?

A

In the advanced plaque macrophages and the products of their apoptosis contribute to SMC cell death (via TNF-α and NO secretion and activation of the Fas pathway) and degradation of the extracellular matrix.

This weakens the fibrous cap promoting plaque rupture, and also promote further inflammation and thrombosis.

The defective clearance of apoptotic cells also reduces anti-inflammatory TGFβ signalling, which signals SMCs to reduce collagen production thus further weakening the cap.

18
Q

How do macrophages promote degradation of the extracellular matrix when they weaken the fibrous cap?

A

By secretion of macrophage derived MMPs (MMP2, 9, 13 and 14) and serine and cysteine proteases (neutrophil elastase and cathepsins L, K and S).

19
Q

What therapeutic strategies aim to prevent LDL invasion of the intima?

A

Many CVD drugs (including statins) aim to prevent formation of the lesions by reduction of plasma atherogenic lipoproteins, reducing retention of them in the intima.

Others target HDLs or mimic their effects to prevent lipoprotein retention, decrease endothelial cell activation and reduce LDL oxidation. However, these treatments only tend to be administered in later stage CVD after presentation of symptoms.

20
Q

What therapeutic strategies aim to regress or ameliorate the lesions? What is a primary limitation to these?

A

Some aim to reduce the number of macrophages in the lesions, either by promoting macrophage emigration or by reducing monocyte entry through neutralisation of chemokines, their receptors, or the adhesion molecules using antibody and gene therapies.

Novel strategies include increasing macrophage cholesterol efflux thus reducing foam cell formation by increasing HDL concentration or upregulating efflux transporters such as ABCG1.

Targeting Delivery to the Plaque is a problem.

21
Q

What methods are being used to target drugs to the lesions?

A

This is an emerging technology, with potential strategies including atherosclerosis directed nanoparticles, encapsulated macrophage targeted-siRNA treatments (allowing for knockdown of genes in macrophages only) and stent-based delivery.

Only 2-3% of the lesions actually lead to symptomatic plaques, so targeting these over the other ones is also important.

Targeting the macrophage processes involved in advanced plaque progression is a strategy.

22
Q

What therapies are used to target the macrophage processes involved in advanced plaque progression?

A

• Pro-inflammation resolution mediators
o Lipoxins
o Resolvins
o IL-10R activators

• MerTK inhibitors
o Involved in recognition of apoptotic cells

• LXR activators
o Increases MerTK expression but also ABCA1/G1

• PPARδ activators

23
Q

What are the main cellular markers used to define monocyte types?

A

Two main cellular markers exist for human monocytes, allowing them to be classified by their expression of them or lack thereof. These are cell differentiation factors 14 and 16 (CD14 and CD16).

CD14 is also called the LPS (lipopolysaccharide) receptor and CD16 the FcyIII receptor.

24
Q

How can monocyte cellular markers be used to classify them into subsets?

A

There are three potential combinations of these, given that one or both of them must be being expressed.

These are denoted CD14++CD16-, CD14++CD16+ and CD14+CD16++ depending on the relative levels of expression (minus signs denoting lack of expression, one plus sign low level expression and two for high level).

25
Q

What are CD14++CD16- monocytes?

A

These are known as classical monocytes, or the pro-inflammatory subset.

This subset has a high affinity for the endothelium and for platelets, as well as having high phagocytosis potential and anti-microbial agent production.

Stimulation of the CD14 (LPS) receptor causes them to produce CCL2 (for which they also express the receptor and are attracted to for transendothelial migration) and IL-10.

26
Q

What are CD14++CD16+ monocytes?

A

These are known as intermediate monocytes, and are thought to be the more atherosclerotic subset.

They share the high platelet affinity of classical monocytes, but differ in several ways. In their immune function they stimulate T-cell proliferation and LPS stimulation leads to TNF-α and IL-1β production.

In atherosclerosis they have notably higher oxLDL uptake and proangiogenic capacity, and express CCR5, the CCL5 chemokine receptor, and hence are stimulated to transendothelial migration by this chemoattractant.

27
Q

What are CD14+CD16++ monocytes?

A

These are known as non-classical monocytes, and are considered as the inflammation resolution subset whose primary role is patrolling, particularly in the vasculature.

These also have high oxLDL uptake, and undergo transendothelial migration in response to CX3CL1 chemokines via CX3CR1 receptors. They also sense viruses and nucleic acids via as TLR7 and TLR8.

28
Q

What is a significant failure of macrophage-targeting therapies?

A

Targeting macrophages in therapy often neglects to differentiate between the more harmful and beneficial macrophages present in the lesion.

The total number of macrophages is not the only measurement of how they contribute to atherosclerosis – the ratio of macrophage phenotypes must also be considered.

29
Q

How are new therapies being generated with regard to macrophage subsets? What is the main problem with this?

A

Treatments now being designed to switch pro-inflammatory classical monocytes to anti-inflammatory non-classical.

However, there are many systems within a macrophage that may be differentially expressed to contribute to it being either pro- or anti-inflammatory, and this calls into question the validity of classing them into subsets when instead they may exist on a phenotypic spectrum.

30
Q

What macrophage subsets can be produced in the lab?

A

Macrophages are generated in the lab by two methods to produce M1 (classically activated) and M2 (non-classically activated) macrophages.

While simplistic, this system is a useful approximation, although both kinds may be present in one plaque and in fact even different subsets of them may act differently in different plaques.

31
Q

What are the human macrophage subsets?

A
M1
M2a, M2c
Mox
M4
Mhem
32
Q

What is the role of M1 macrophages in atherosclerosis?

A

It is however believed that M1 macrophages are the primary type present in atherosclerosis, due to their being induced by oxLDLs, necrotic core components and associated microbial products.

M1 macrophages produce a large amount of ROS and RNS as well as pro-inflammatory cytokines such as TNF and ILs 1, 6 and 12. These increase and sustain the inflammatory response, supposedly in response to infection, providing resistance to pathogens, tumours and tissue disruptive reactions.

33
Q

How are M1 macrophages produced in the lab?

A

They are produced in the lab by IFN-γ and LPS signalling, which activates master TFs such as STAT-1, NF-Κb, and IRF-5.

34
Q

What are the general features of M2 macrophages?

A

These express high levels of scavenger receptors and anti-inflammatory factors. Several M2 subtypes have been described, depending on the factors they express/respond to.

35
Q

What is the difference between the different M2 macrophage subtypes?

A

M2a macrophages express IL-4 and 13, and promote tissue repair and remodelling, as well as angiogenesis, parasite encapsulation and allergic response.

M2c macrophages express TGFβ and IL-10, and are involved in immune repression and associated with tumour promotion. They are also found localised to atherosclerotic plaques, where they have a protective role.

36
Q

What effect does M2 Macrophage presence have on lesions?

A

In atherosclerotic lesions, M2 macrophages have a distinct distribution pattern to M2, colocalising with IL-4 in stable, cell rich areas.

They are atheroprotective through their reduction of lipid accumulation, increased phagocytic activity, their decreased LDL uptake and cholesterol transporter expression with increased ACAT activity.

The evidence of the atheroprotective role is less abundant than the evidence for the atherogenic role of M1 macrophages.

37
Q

What are the characteristics of macrophages of the Mox subtype?

A

Activated by oxidised PLs that accumulate in hypoxic tissues. Characterised by strong anti-oxidant production (NFR2), and decreased chemotactic and phagocytic activity.

38
Q

What are the characteristics of macrophages of the Mox subtype?

A

Activated by CXCL4. Lower expression of scavenger receptors, increased expression of cholesterol transporters.

39
Q

What are the characteristics of macrophages of the Mhem subtype?

A

This is activated by haemoglobin, as a response to haemorrhage. They are M2-like, expressing MR and CD16, and being devoid of the lipids typically found in foam cells due to their resistance to cholesterol loading and increased cholesterol transporter expression.

These have increased ferroportin expression, reducing the intracellular iron concentration, and produce fewer ROS than other macrophages. They are thought to protect from oxidant stress.

40
Q

What monocyte subsets exist in mice?

A

Mice have only two subsets, depending on how highly they express a particular protein: Ly6C. The two subsets are therefore noted as Ly6C^hi (the pro-inflammatory subset) and Ly6C^lo (the inflammation resolution subset).

These essentially correspond to the classical and non-classical human monocyte subsets respectively.

41
Q

What are the features of Ly6C^hi mouse monocytes?

A

These are potently atherogenic, being recruited to inflamed endothelium and participating in acute inflammatory response.

They are the first to appear and account for half of the mouse monocytes, but this number increases to 80% in hypercholesterolaemic mice. They respond to CCL2 chemokines through their CCR2 receptors, and are thought to be M1 macrophage precursors.

42
Q

What are the features of Ly6C^lo mouse monocytes?

A

These are attracted to CX3CL1 via CX3CR1 receptors, and enter plaques far less frequently. They do however patrol the vasculature to allow for rapid invasion in case of damage or infection, but are associated with reduced inflammation.

They are also thought to be involved in homeostatic function and secretion of survival signals, and may be M2 macrophage precursors.